Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, estudio No reclutando aún

Not Yet Recruiting

ID del estudio CA266-0001  |   NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Ícono de advertencia
Lo sentimos, este estudio aún no acepta participantes.
Marque esta página como favorita para volver a consultarla en una fecha posterior.  También puede hacer clic en el botón “Verificar su elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad

Resumen

  • Phase 3
  • Ícono de género masculino y femenino
  • 18+
  • 125
  • Ícono de BMS, estudio No reclutando aún
    Not Yet Recruiting

Descripción general

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must have a histologically
    1. or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
      1. Participants must have received at least 2 cycles of platinum-based concurrent chemotherapy (a total dose of radiation of at least 54 Gy).
        1. Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
          1. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.

            Criterios de exclusión

            Criterios de exclusión Icon
            • Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements.
              1. Participants must not have an active autoimmune disease.
                1. Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage.
                  1. Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or current or suspected ILD or pneumonitis.
                    1. Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
                      Información Adicional *
                      • Other protocol-defined Inclusion/Exclusion criteria apply.

                        Opciones de tratamiento

                        Brazos del estudio

                        INTERVENCIÓN ASIGNADA

                        Brazos del estudio

                        Experimental: Arm A

                        INTERVENCIÓN ASIGNADA
                        • Drug: Pumitamig

                        Brazos del estudio

                        Active Comparator: Arm B

                        INTERVENCIÓN ASIGNADA
                        • Drug: Durvalumab
                        Vuelva a consultar más tarde para encontrar un sitio de reclutamiento o encuentre otro estudio haciendo clic en “Verificar su elegibilidad”
                        Verifique su elegibilidad
                        Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                        Compatibilizar con un estudio
                        Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                        Seleccione una ubicación del centro del estudio
                        Seleccione una ubicación del centro del estudio que sea conveniente para usted
                        Registrarse
                        Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                        Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias